F-127-PEI co-delivering docetaxel and TFPI-2 plasmid for nasopharyngeal cancer therapy

Liu, Tao; Zhang, Xinyu; Jin, Chenghao; Wang, Yigang; Wu, Xidong; Ji, Gang; Wu, Ting; Nie, Guohui

doi:10.1016/j.msec.2015.12.049

Cited by 19 publications

(14 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with paclitaxel, DTX exhibits a better affinity to tubulin and higher anti-tumor bioactivity. DTX has been approved by the Food and Drug Administration (FDA) for the treatment of various solid tumors such as locally advanced and metastatic breast cancer, non-small cell lung cancer, androgen-independent prostate cancer, and advanced gastric cancers (Gao et al, 2008;Liu et al, 2008Liu et al, , 2016. However, because of the poor aqueous solubility (6-7 lg/mL) of DTX, Tween-80 and ethanol have to be added in its marketed formulation (Taxotere V R ) as the emulsifier, resulting in undesirable side effects, including short-lasting neurotoxicity, hypersensitivity, fluid retention, hemolysis, and alopecia (Balakrishnan et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

Drug-interactive mPEG- b -PLA-Phe(Boc) micelles enhance the tolerance and anti-tumor efficacy of docetaxel

et al. 2020

View full text Add to dashboard Cite

Docetaxel (DTX) is one of the most promising chemotherapeutic agents for a variety of solid tumors. However, the clinical efficacy of the marketed formulation, Taxotere V R , is limited due to its poor aqueous solubility, side effects caused by the emulsifier, and low selective DTX distribution in vivo. Here a facile, well-defined, and easy-to-scale up DTX-loaded N-(tert-butoxycarbonyl)-L-phenylalanine endcapped methoxy-poly(ethylene glycol)-block-poly(D,L-lactide) (mPEG-b-PLA-Phe(Boc)) micelles (DTX-PMs) were prepared in an effort to develop a less toxic and more efficacious docetaxel formulation. The physicochemical properties, pharmacokinetics, biodistribution, and in vivo anti-tumor efficacy were evaluated in comparison to the marketed DTX formulation Taxotere V R. DTX was successfully encapsulated in the hydrophobic micellar core with a high encapsulation efficiency (> 95%) and a high drug loading capacity (4.81 ± 0.08%). DTX-PMs exhibited outstanding stability in the aqueous environment due to the strong interactions between the terminal amino acid residues and docetaxel. The pharmacokinetic study in Sprague-Dawley rats revealed higher DTX concentrations in both whole blood and plasma for the group treated with DTX-PMs than that treated with Taxotere V R due to the improved stability of the micellar formulation. In human non-small cell lung cancer (A549) tumor-bearing Balb/c nude mice, DTX-PMs significantly improved DTX accumulation and stalled DTX elimination in tumors than in bone marrow. Furthermore, only by half of the DTX dosage, our DTX/mPEG-b-PLA-Phe(Boc) micelles can achieve similar therapeutic effects as Taxotere V R. Altogether, DTX-PMs hold great promise as a simple and effective drug delivery system for cancer chemotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Drug-interactive mPEG- b -PLA-Phe(Boc) micelles enhance the tolerance and anti-tumor efficacy of docetaxel

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The presence of biodegradable components along the polymeric backbone would allow the copolymer components to degrade into smaller fragments and eventually excreted from the body. Research have reported the use of different types of thermoresponsive polymer systems such as Pluronic F127 hydrogels which consists of triblock copolymers of poly(ethylene glycol), poly(propylene glycol), and poly(ethylene glycol) blocks (PEG–PPG–PEG) . However, this triblock copolymer system is non‐biodegradable.…”

Section: Introductionmentioning

confidence: 99%

New Poly[(R )-3-hydroxybutyrate-co -4-hydroxybutyrate] (P3HB4HB)-Based Thermogels

Wee

Liow

Liu

et al. 2017

Macromol. Chem. Phys.

View full text Add to dashboard Cite

Poly[(R)‐3‐hydroxybutyrate] (P3HB) is a potential candidate for biomaterials due to its biocompatibility and biodegradability. However, P3HB needs to have tunable hydrophobicity, modification through chemical functionalization and the right hydrolytic stability to increase their potential for water‐based biomedical applications such as using them as in situ forming gels for drug delivery. This work focuses on using a copolymer, poly[(R)‐3‐hydroxybutyrate‐co‐4‐hydroxybutyrate] (P3HB4HB) in a thermogelling multiblock system with polypropylene glycol and polyethylene glycol to study the effect of the hydrophobic P3HB4HB on gelation properties, degradation, and drug release rates with reference to P3HB. Thermogels containing P3HB4HB segments show lower critical micellization concentration values in a range from 3 × 10−4 to 1.08 × 10−3 g mL−1 and lower critical gelation concentration values ranging from 2 to 6 wt% than that of gels containing P3HB. Furthermore, gels containing P3HB4HB degrade at a slower rate than the gels containing P3HB. Drug release studies of 5 µg mL−1 of doxorubicin show that gels containing P3HB4HB exhibit sustained release although the release rates are faster than gels containing P3HB. However, this can be modified by varying the concentration of the gels used. Process optimization of purifying the starting material is one important factor before the synthesis of these biomaterials.

show abstract

“…It has been reported that the drugs containing benzene groups could stack on the GO plane effectively, so GO showed higher drugs loading amount than micelles and other usual carriers (Ma et al., 2012; Rahmani et al., 2018; Liu et al., 2018). In this work, the loading amount of DOC in Tf-HPAA-GO/DOC complex was determined as 5.6% (w/w) by HPLC analysis, much higher than our previous work (Liu et al., 2016).…”

Section: Resultsmentioning

confidence: 61%

Transferrin-targeting redox hyperbranched poly(amido amine)-functionalized graphene oxide for sensitized chemotherapy combined with gene therapy to nasopharyngeal carcinoma

Liu

Wu³

et al. 2019

Drug Delivery

Self Cite

View full text Add to dashboard Cite

show abstract

F-127-PEI co-delivering docetaxel and TFPI-2 plasmid for nasopharyngeal cancer therapy

Cited by 19 publications

References 34 publications

Drug-interactive mPEG- b -PLA-Phe(Boc) micelles enhance the tolerance and anti-tumor efficacy of docetaxel

Drug-interactive mPEG- b -PLA-Phe(Boc) micelles enhance the tolerance and anti-tumor efficacy of docetaxel

New Poly[(R )-3-hydroxybutyrate-co -4-hydroxybutyrate] (P3HB4HB)-Based Thermogels

Transferrin-targeting redox hyperbranched poly(amido amine)-functionalized graphene oxide for sensitized chemotherapy combined with gene therapy to nasopharyngeal carcinoma

Contact Info

Product

Resources

About